Top Markets
#1 TENDIES TENDIES +46.92%
#2 Cash Cat Cash Cat +32.77%
#3 Threshold Network Threshold Network +21.74%
#4 Asteroid Shiba Asteroid Shiba +17.72%
#5 OSK OSK +15.83%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 Magma Finance Magma Finance +10.26%
#8 MarsCoin MarsCoin +10.22%
#9 龙虾 (Lobster) 龙虾 (Lobster) +10.07%
#10 Kite Kite +9.67%
Coin of the day
TENDIES TENDIES
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Kedudukan dalam Saham #16725
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Harga Saham
$3.78
Disegerakkan terakhir: 2026-03-17
Modal Pasaran
$276.54M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
45.53%
Negara
CA
Perdagangan NervGen Pharma Corp. (NGEN)

Kategori

Healthcare
Pendapatan untuk NervGen Pharma Corp. (NGEN)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini NervGen Pharma Corp., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi NervGen Pharma Corp. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH